APO Research
Talk to an analyst

APO RESEARCH · REPORT

Assisted Reproduction Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Assisted Reproduction Drug Market Outlook and Growth Opportunities 2026

30 December 2025198 pages

Choose your research edition.

Industry ResearchAssisted Reproduction Drug Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Assisted Reproduction Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Assisted Reproduction Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Assisted Reproduction Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Assisted Reproduction Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Assisted Reproduction Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Assisted Reproduction Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Assisted Reproduction Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Assisted Reproduction Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Assisted Reproduction Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Assisted Reproduction Drug market include Ipsen Pharma Biotech, Zhejiang Xianju Pharmaceutical Co., Ltd., Solvay Pharma, Shanghai First Biochemical Pharmaceutical Co. LTD, Merck Sharp & Dohme, Merck Serono, Livzon Group and GenSci, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Assisted Reproduction Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Assisted Reproduction Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Assisted Reproduction Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Assisted Reproduction Drug market.

Assisted Reproduction Drug Segment by Company

Ipsen Pharma Biotech

Zhejiang Xianju Pharmaceutical Co., Ltd.

Solvay Pharma

Shanghai First Biochemical Pharmaceutical Co. LTD

Merck Sharp & Dohme

Merck Serono

Livzon Group

GenSci

Assisted Reproduction Drug Segment by Type

Progestogen Hormone

Human Choroinic Gonadotrophin

Gonadotropin Releasing Hormone

Follicle-stimulating Hormone

Assisted Reproduction Drug Segment by Application

Controlled Ovarian Hyperstimulation

luteal Support

Down Regultion

Induced Ovulation

Assisted Reproduction Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Assisted Reproduction Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Assisted Reproduction Drug key companies, revenue, market share, and recent developments.

3. To split the Assisted Reproduction Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Assisted Reproduction Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Assisted Reproduction Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Assisted Reproduction Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Assisted Reproduction Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Assisted Reproduction Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Assisted Reproduction Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Assisted Reproduction Drug industry.

Chapter 3: Detailed analysis of Assisted Reproduction Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Assisted Reproduction Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Assisted Reproduction Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Assisted Reproduction Drug Industry Trends Table 2. Assisted Reproduction Drug Industry Drivers Table 3. Assisted Reproduction Drug Industry Opportunities and Challenges Table 4. Assisted Reproduction Drug Industry Restraints Table 5. Global Assisted Reproduction Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Assisted Reproduction Drug Revenue Share by Company (2021-2026) Table 7. Global Assisted Reproduction Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Assisted Reproduction Drug Key Company Manufacturing Base & Headquarters Table 9. Global Assisted Reproduction Drug Company, Product Type & Application Table 10. Global Assisted Reproduction Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Assisted Reproduction Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Progestogen Hormone Table 15. Significant Companies of Human Choroinic Gonadotrophin Table 16. Significant Companies of Gonadotropin Releasing Hormone Table 17. Significant Companies of Follicle-stimulating Hormone Table 18. Global Assisted Reproduction Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Assisted Reproduction Drug Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Assisted Reproduction Drug Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Assisted Reproduction Drug Sales Value Share by Type (2021-2026) Table 22. Global Assisted Reproduction Drug Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Controlled Ovarian Hyperstimulation Table 24. Significant Companies of luteal Support Table 25. Significant Companies of Down Regultion Table 26. Significant Companies of Induced Ovulation Table 27. Global Assisted Reproduction Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Assisted Reproduction Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Assisted Reproduction Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Assisted Reproduction Drug Sales Value Share by Application (2021-2026) Table 31. Global Assisted Reproduction Drug Sales Value Share by Application (2027-2032) Table 32. Global Assisted Reproduction Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Assisted Reproduction Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Assisted Reproduction Drug Sales Value Share by Region (2021-2026) Table 35. Global Assisted Reproduction Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Assisted Reproduction Drug Sales Value Share by Region (2027-2032) Table 37. Global Assisted Reproduction Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Assisted Reproduction Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Assisted Reproduction Drug Sales Value Market Share by Country (2021-2026) Table 40. Global Assisted Reproduction Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Assisted Reproduction Drug Sales Value Market Share by Country (2027-2032) Table 42. Ipsen Pharma Biotech Company Information Table 43. Ipsen Pharma Biotech Business Overview Table 44. Ipsen Pharma Biotech Assisted Reproduction Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Ipsen Pharma Biotech Assisted Reproduction Drug Product Portfolio Table 46. Ipsen Pharma Biotech Recent Development Table 47. Zhejiang Xianju Pharmaceutical Co., Ltd. Company Information Table 48. Zhejiang Xianju Pharmaceutical Co., Ltd. Business Overview Table 49. Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Product Portfolio Table 51. Zhejiang Xianju Pharmaceutical Co., Ltd. Recent Development Table 52. Solvay Pharma Company Information Table 53. Solvay Pharma Business Overview Table 54. Solvay Pharma Assisted Reproduction Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Solvay Pharma Assisted Reproduction Drug Product Portfolio Table 56. Solvay Pharma Recent Development Table 57. Shanghai First Biochemical Pharmaceutical Co. LTD Company Information Table 58. Shanghai First Biochemical Pharmaceutical Co. LTD Business Overview Table 59. Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Product Portfolio Table 61. Shanghai First Biochemical Pharmaceutical Co. LTD Recent Development Table 62. Merck Sharp & Dohme Company Information Table 63. Merck Sharp & Dohme Business Overview Table 64. Merck Sharp & Dohme Assisted Reproduction Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Merck Sharp & Dohme Assisted Reproduction Drug Product Portfolio Table 66. Merck Sharp & Dohme Recent Development Table 67. Merck Serono Company Information Table 68. Merck Serono Business Overview Table 69. Merck Serono Assisted Reproduction Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Merck Serono Assisted Reproduction Drug Product Portfolio Table 71. Merck Serono Recent Development Table 72. Livzon Group Company Information Table 73. Livzon Group Business Overview Table 74. Livzon Group Assisted Reproduction Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Livzon Group Assisted Reproduction Drug Product Portfolio Table 76. Livzon Group Recent Development Table 77. GenSci Company Information Table 78. GenSci Business Overview Table 79. GenSci Assisted Reproduction Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. GenSci Assisted Reproduction Drug Product Portfolio Table 81. GenSci Recent Development Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. Assisted Reproduction Drug Product Image Figure 2. Global Assisted Reproduction Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Assisted Reproduction Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Assisted Reproduction Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Progestogen Hormone Image Figure 8. Human Choroinic Gonadotrophin Image Figure 9. Gonadotropin Releasing Hormone Image Figure 10. Follicle-stimulating Hormone Image Figure 11. Global Assisted Reproduction Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Assisted Reproduction Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Assisted Reproduction Drug Sales Value Share by Type (2021-2032) Figure 14. Controlled Ovarian Hyperstimulation Image Figure 15. luteal Support Image Figure 16. Down Regultion Image Figure 17. Induced Ovulation Image Figure 18. Global Assisted Reproduction Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Assisted Reproduction Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Assisted Reproduction Drug Sales Value Share by Application (2021-2032) Figure 21. Global Assisted Reproduction Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Assisted Reproduction Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Assisted Reproduction Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America Assisted Reproduction Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Assisted Reproduction Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Assisted Reproduction Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Assisted Reproduction Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Assisted Reproduction Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Assisted Reproduction Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America Assisted Reproduction Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Assisted Reproduction Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Assisted Reproduction Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Assisted Reproduction Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Progestogen Hormone
  • Human Choroinic Gonadotrophin
  • Gonadotropin Releasing Hormone
  • Follicle-stimulating Hormone
Applications
  • Controlled Ovarian Hyperstimulation
  • luteal Support
  • Down Regultion
  • Induced Ovulation
Companies covered
  • Ipsen Pharma Biotech
  • Zhejiang Xianju Pharmaceutical Co., Ltd.
  • Solvay Pharma
  • Shanghai First Biochemical Pharmaceutical Co. LTD
  • Merck Sharp & Dohme
  • Merck Serono
  • Livzon Group
  • GenSci

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Assisted Reproduction Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Assisted Reproduction Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Assisted Reproduction Drug Market Dynamics
  1. 2.1 Assisted Reproduction Drug Industry Trends
  2. 2.2 Assisted Reproduction Drug Industry Drivers
  3. 2.3 Assisted Reproduction Drug Industry Opportunities and Challenges
  4. 2.4 Assisted Reproduction Drug Industry Restraints
3 Assisted Reproduction Drug Market by Company
  1. 3.1 Global Assisted Reproduction Drug Company Revenue Ranking in 2025
  2. 3.2 Global Assisted Reproduction Drug Revenue by Company (2021-2026)
  3. 3.3 Global Assisted Reproduction Drug Company Ranking (2024-2026)
  4. 3.4 Global Assisted Reproduction Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Assisted Reproduction Drug Company Product Type and Application
  6. 3.6 Global Assisted Reproduction Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Assisted Reproduction Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Assisted Reproduction Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Assisted Reproduction Drug Market by Type
  1. 4.1 Assisted Reproduction Drug Type Introduction
  2. 4.1.1 Progestogen Hormone
  3. 4.1.2 Human Choroinic Gonadotrophin
  4. 4.1.3 Gonadotropin Releasing Hormone
  5. 4.1.4 Follicle-stimulating Hormone
  6. 4.2 Global Assisted Reproduction Drug Sales Value by Type
  7. 4.2.1 Global Assisted Reproduction Drug Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Assisted Reproduction Drug Sales Value by Type (2021-2032)
  9. 4.2.3 Global Assisted Reproduction Drug Sales Value Share by Type (2021-2032)
5 Assisted Reproduction Drug Market by Application
  1. 5.1 Assisted Reproduction Drug Application Introduction
  2. 5.1.1 Controlled Ovarian Hyperstimulation
  3. 5.1.2 luteal Support
  4. 5.1.3 Down Regultion
  5. 5.1.4 Induced Ovulation
  6. 5.2 Global Assisted Reproduction Drug Sales Value by Application
  7. 5.2.1 Global Assisted Reproduction Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Assisted Reproduction Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Assisted Reproduction Drug Sales Value Share by Application (2021-2032)
6 Assisted Reproduction Drug Regional Value Analysis
  1. 6.1 Global Assisted Reproduction Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Assisted Reproduction Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Assisted Reproduction Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Assisted Reproduction Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Assisted Reproduction Drug Sales Value (2021-2032)
  7. 6.3.2 North America Assisted Reproduction Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Assisted Reproduction Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Assisted Reproduction Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Assisted Reproduction Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Assisted Reproduction Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Assisted Reproduction Drug Sales Value (2021-2032)
  16. 6.6.2 South America Assisted Reproduction Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Assisted Reproduction Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Assisted Reproduction Drug Sales Value Share by Country, 2025 VS 2032
7 Assisted Reproduction Drug Country-level Value Analysis
  1. 7.1 Global Assisted Reproduction Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Assisted Reproduction Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Assisted Reproduction Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Assisted Reproduction Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Assisted Reproduction Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Assisted Reproduction Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Assisted Reproduction Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Ipsen Pharma Biotech
  2. 8.1.1 Ipsen Pharma Biotech Company Information
  3. 8.1.2 Ipsen Pharma Biotech Business Overview
  4. 8.1.3 Ipsen Pharma Biotech Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Ipsen Pharma Biotech Assisted Reproduction Drug Product Portfolio
  6. 8.1.5 Ipsen Pharma Biotech Recent Developments
  7. 8.2 Zhejiang Xianju Pharmaceutical Co., Ltd.
  8. 8.2.1 Zhejiang Xianju Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Zhejiang Xianju Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Product Portfolio
  12. 8.2.5 Zhejiang Xianju Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Solvay Pharma
  14. 8.3.1 Solvay Pharma Company Information
  15. 8.3.2 Solvay Pharma Business Overview
  16. 8.3.3 Solvay Pharma Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Solvay Pharma Assisted Reproduction Drug Product Portfolio
  18. 8.3.5 Solvay Pharma Recent Developments
  19. 8.4 Shanghai First Biochemical Pharmaceutical Co. LTD
  20. 8.4.1 Shanghai First Biochemical Pharmaceutical Co. LTD Company Information
  21. 8.4.2 Shanghai First Biochemical Pharmaceutical Co. LTD Business Overview
  22. 8.4.3 Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Product Portfolio
  24. 8.4.5 Shanghai First Biochemical Pharmaceutical Co. LTD Recent Developments
  25. 8.5 Merck Sharp & Dohme
  26. 8.5.1 Merck Sharp & Dohme Company Information
  27. 8.5.2 Merck Sharp & Dohme Business Overview
  28. 8.5.3 Merck Sharp & Dohme Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Sharp & Dohme Assisted Reproduction Drug Product Portfolio
  30. 8.5.5 Merck Sharp & Dohme Recent Developments
  31. 8.6 Merck Serono
  32. 8.6.1 Merck Serono Company Information
  33. 8.6.2 Merck Serono Business Overview
  34. 8.6.3 Merck Serono Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Serono Assisted Reproduction Drug Product Portfolio
  36. 8.6.5 Merck Serono Recent Developments
  37. 8.7 Livzon Group
  38. 8.7.1 Livzon Group Company Information
  39. 8.7.2 Livzon Group Business Overview
  40. 8.7.3 Livzon Group Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Livzon Group Assisted Reproduction Drug Product Portfolio
  42. 8.7.5 Livzon Group Recent Developments
  43. 8.8 GenSci
  44. 8.8.1 GenSci Company Information
  45. 8.8.2 GenSci Business Overview
  46. 8.8.3 GenSci Assisted Reproduction Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GenSci Assisted Reproduction Drug Product Portfolio
  48. 8.8.5 GenSci Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst